437 related articles for article (PubMed ID: 15364449)
61. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
62. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
[TBL] [Abstract][Full Text] [Related]
63. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity.
Lin CT; Chang TC; Shaw SW; Cheng PJ; Huang CT; Chao A; Soong YK; Lai CH
Vaccine; 2006 Sep; 24(37-39):6199-207. PubMed ID: 16824651
[TBL] [Abstract][Full Text] [Related]
64. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
[TBL] [Abstract][Full Text] [Related]
65. [Immunogenicity of mutant and wild HPV16 DNA vaccines].
Zuo YG; Wang JB; Jin HZ; Yue-hua L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771
[TBL] [Abstract][Full Text] [Related]
66. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
67. [Construction of recombinant vaccinia virus co-expressing mutant E6 plus E7 proteins and detection of its immunogenicity and antitumor response].
Zhi H; Han L; Ren J; Tian H; Luo W; Liang Y; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):341-4. PubMed ID: 12665900
[TBL] [Abstract][Full Text] [Related]
68. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.
Qin Y; Wang XH; Cui HL; Cheung YK; Hu MH; Zhu SG; Xie Y
Gynecol Oncol; 2005 Feb; 96(2):475-83. PubMed ID: 15661238
[TBL] [Abstract][Full Text] [Related]
69. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW
Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672
[TBL] [Abstract][Full Text] [Related]
70. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
71. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
72. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen.
Cheng WF; Hung CH; Chai CY; Hsu KF; He L; Ling M; Wu TC
J Virol; 2001 Mar; 75(5):2368-76. PubMed ID: 11160740
[TBL] [Abstract][Full Text] [Related]
73. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
[TBL] [Abstract][Full Text] [Related]
74. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
Di Bonito P; Grasso F; Mochi S; Petrone L; Fanales-Belasio E; Mei A; Cesolini A; Laconi G; Conrad H; Bernhard H; Dembek CJ; Cosma A; Santini SM; Lapenta C; Donati S; Muratori C; Giorgi C; Federico M
Virology; 2009 Dec; 395(1):45-55. PubMed ID: 19800648
[TBL] [Abstract][Full Text] [Related]
75. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.
Kang TH; Chung JY; Monie A; Pai SI; Hung CF; Wu TC
Gene Ther; 2010 Apr; 17(4):531-40. PubMed ID: 19940864
[TBL] [Abstract][Full Text] [Related]
76. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine.
Han HD; Song CK; Park YS; Noh KH; Kim JH; Hwang T; Kim TW; Shin BC
Int J Pharm; 2008 Feb; 350(1-2):27-34. PubMed ID: 17897800
[TBL] [Abstract][Full Text] [Related]
77. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
[TBL] [Abstract][Full Text] [Related]
78. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
79. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
Ji H; Wang TL; Chen CH; Pai SI; Hung CF; Lin KY; Kurman RJ; Pardoll DM; Wu TC
Hum Gene Ther; 1999 Nov; 10(17):2727-40. PubMed ID: 10584920
[TBL] [Abstract][Full Text] [Related]
80. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
